AzTrials
AzTrials

Genital ProlapseREPAIRNCT06296316

Real-Life Use of Transabdominal Restorelle® Meshes in Apical Prolapse Repair

An observational study of Genital Prolapse, run by Coloplast A/S at 6 sites in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to prospectively follow patients after a sacrocolpopexy with Restorelle® mesh for apical prolapse repair as part of routine care. It will help to describe the safety profile and to confirm the clinical benefits of Restorelle mesh for at least 5 to 8 years post-surgery. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Genital Prolapse
What is being tested?
Restorelle Polypropylene Mesh
Type of treatment
Medical device
How many people
39 participants
Where
6 sitesFrance
Study dates
21 Nov 2023to 6 Nov 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult female patients presenting with apical pelvic organ prolapse which is clinically indicated for a surgical treatment with Restorelle mesh

Who may be able to join

  • Female patient of at least 18 years old
  • Patient presenting apical pelvic organ prolapse and being eligible to surgical treatment
  • Surgeon having decided to treat the patient with a Restorelle mesh as per its CE mark indication and IFU, before patient inclusion
  • Patient having received appropriate information and counselling before mesh implantation
  • Patient has been provided written informed consent

Who cannot join

  • Patient currently pregnant or breastfeeding
  • Patient being deprived of liberty by a judicial or administrative decision, or who is under a measure of legal protection

Trial locations and contacts

6 sites in 1 country.

6 sites in 1 country

France6 sites
  • Polyclinique de la Baie

    Avranches, Choisir Une Région, 50300

  • CHU Pellegrin

    Bordeaux, 33076

  • CH La Rochelle

    La Rochelle, 17019

  • Clinique Bon Secours

    Le Puy-en-Velay, 43000

  • Institut Mutualiste Montsouris

    Paris, 75014

  • CH de Saintonge

    Saintes, 17108

Other trials in France

About this study

Official title: Real-Life Use of Transabdominal Restorelle® Meshes in Apical Prolapse Repair: an Observational Post-Market Clinical Study

The purpose of this study is to prospectively follow patients after a sacrocolpopexy with Restorelle® mesh for apical prolapse repair as part of routine care. It will help to describe the safety profile and to confirm the clinical benefits of Restorelle mesh for at least 5 to 8 years post-surgery.

Read the detailed description

This study is a non-interventional, multicenter and post market clinical follow-up in adult women with apical prolapse under normal conditions of use (after a sacrocolpopexy with Restorelle mesh for apical prolapse repair as part of routine care). The patient will be followed for 1 year (or less) by the investigator as per local usual practice. At the same time, the patient will be followed via PRO (Patient Reported Outcomes) over a period of 5 to 8 years.

Being tested
Restorelle Polypropylene Mesh
Keywords
Apical prolapse, Transabdominal mesh, Pelvic organ prolapse, Sacrocolpopexy, Sacrocervicopexy, Sacrohysteropexy
Medical subject headings
Pelvic Organ Prolapse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Restorelle Polypropylene MeshDevice

    The Coloplast Restorelle® Polypropylene Mesh is a Class III, implantable, permanent, non-absorbable, single use device indicated to restore female pelvic floor anatomy by providing anatomical support and suspension as a bridging material to support deficient fascia that resulted in descent of the female pelvic organs (pelvic organ prolapse).

    Restorelle mesh is a synthetic, macroporous mesh constructed of medical grade knitted, monofilament polypropylene.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The incidence rate of a surgical reintervention related to Restorelle mesh use over at least the 5 first years of post-index procedure follow-up

    Measured: up to 5 years

Secondary outcomes (24)
  1. Incidence rate of surgical reintervention related to Restorelle mesh use in patients

    Measured: through study completion, at least 5 and up to 8 years

  2. Number of patients who have only had surgical reintervention not related to Restorelle mesh use

    Measured: through study completion, at least 5 and up to 8 years

  3. Percentage of patients who have only had surgical reintervention not related to Restorelle mesh use

    Measured: through study completion, at least 5 and up to 8 years

  4. Number of patients who have had more than 1 surgical reintervention (unrelated to mesh use)

    Measured: 5 years ; up to 8-year after index procedure

  5. Percentage of patients who have had more than 1 surgical reintervention (unrelated to mesh use)

    Measured: 5 years ; up to 8-year after index procedure

  6. Description of patients who have had more than 1 surgical reintervention (unrelated to mesh use)

    Measured: 5 years ; up to 8-year after index procedure

  7. Patient impression of improvement of surgical reintervention assessed by the PGI-I-Reintervention

    Patient Global Impression of Improvement (PGI-I) is a 7-point scale that provides a single global measure of condition improvement from 'very much better' to 'very much worse' after treatment. The surgery is defined as successful if the patient felt "very much better" or "much better". In case of reintervention, the patient will complete a PGI-I-Reintervention (same questionnaire as PGI-I) at 6 months after surgical reintervention.

    Measured: 6 months after surgical reintervention

  8. Number of Adverse Device Effect

    Measured: through study completion, at least 5 and up to 8 years

  9. Percentage of Adverse Device Effect

    Measured: through study completion, at least 5 and up to 8 years

  10. Number of Restorelle mesh Device Deficiencies

    Measured: through study completion, at least 5 and up to 8 years

  11. Percentage of Restorelle mesh Device Deficiencies

    Measured: through study completion, at least 5 and up to 8 years

  12. Description of Restorelle mesh Device Deficiencies

    The description of identified Restorelle mesh Device Deficiencies and categorized according to the association or not with Adverse Device Effect (ADE) or Serious ADE

    Measured: through study completion, at least 5 and up to 8 years

  13. Monitoring of postoperative pain related to Restorelle mesh use using the modified TOMUS/PREM questionnaire

    Post-operative pain will be reported and evaluated by the patient using the modified TOMUS/PREM questionnaire through:

    • Location and Intensity VAS
    • Pain duration: acute or chronic (more than 6 months)
    • Treatment: types, drug name (if medication) and duration
    • Persistent pain, beyond 2 weeks, will be defined as having
    1. pain intensity ≥ 40 (VAS) at any of locations (lower abdomen, vagina, lower back and back of legs/buttocks) or during any activity or
    2. pain medication use.

    Measured: through study completion, at least 5 and up to 8 years

  14. Changes of prolapse symptoms

    The changes in the Pelvic Floor Disability Index (PFDI-20 questionnaire) total score and sub scores.

    Pelvic Floor Distress Inventory (PDFI-20) is comprised of 3 subscales for a total of 20 questions. Each question begins with a "yes" or "no" response. If "yes," the patient must indicate how much bowl, bladder, or pelvic symptoms have been bothering them in the past 3 months on a 4-point scale that ranges from "not at all" (0) to "quite a bit" (4). The scale scores are found individually by calculating the mean value of their corresponding questions and then multiplying by 25 to obtain a value that ranges from 0 to 100 (with higher scores indicating more distress/dysfunction). The sum of the 3 scales are added together to get the PFDI-20 summary score, which ranges from 0 to 300.

    Measured: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)

  15. Prolapse symptoms - number

    The number of patients rating "yes" at "vaginal bulge" determined by the PFDI-20/POPDI-6 and requiring additional treatment for POP since index procedure

    Measured: 12 months ; 5 years

  16. Prolapse symptoms - percentage

    The percentage of patients rating "yes" at "vaginal bulge" determined by the PFDI-20/POPDI-6 and requiring additional treatment for POP since index procedure

    Measured: 12 months ; 5 years

  17. Assessment of health related quality of life using the EQ-5D-5L questionnaire

    The changes in QoL total score using EQ-5D-5L and their evolution. The General Health Outcome Status questionnaire (EQ-5D-5L) consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions which are divided into 5 levels of perceived problems: from level 1 indicating no problem to level 5 indicating extreme problems. The patient indicates her health state in each of the 5 dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, from 'The best health you can imagine' to 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgment.

    Measured: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)

  18. Assessment of health related quality of life using the PFIQ-7 questionnaire

    The changes in QoL total score using the Pelvic Floor Impact Questionnaire (PFIQ-7) and their evolution.

    Pelvic Floor Impact Questionnaire (PFIQ-7) consists of 7 questions. The responses for each question range from "not at all" (0) to "quite a bit" (3). To get scale scores, the mean of each of the 3 scales is individually calculated, which ranges from 0-3, this number is then multiplied by 100 and then divided by 3. The scale scores are then added together to get the total PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.

    Measured: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)

  19. Assessment of the sexual functioning by the PISQ-IR questionnaire

    Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA revised (PISQ-IR): is composed of 20 items including the scales for arousal \& orgasm, partner related, condition specific, global quality, condition impact and desire. The number of cases for each scale that can be scored. The mean and standard deviation are provided for each scale.

    Measured: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)

  20. Assessment of the sexual functioning by the changes in dyspareunia status of patients who are sexually active.

    Measured: Pre-index procedure ; 12 months

  21. Number of patients defining success via patient global impression of improvement (PGI-I) scale

    Patient Global Impression of Improvement (PGI-I) is a 7-point scale that provides a single global measure of condition improvement from 'very much better' to 'very much worse' after treatment. The surgery is defined as successful if the patient felt "very much better" or "much better".

    Measured: 2 months ; 12 months ; Every year (at least 5 and up to 8 years)

  22. Percentage of patients defining success via patient global impression of improvement (PGI-I) scale

    Patient Global Impression of Improvement (PGI-I) is a 7-point scale that provides a single global measure of condition improvement from 'very much better' to 'very much worse' after treatment. The surgery is defined as successful if the patient felt "very much better" or "much better".

    Measured: 2 months ;12 months ; Every year (at least 5 and up to 8 years)

  23. Number of patients satisfied after the index procedure as assessed by the Surgical Satisfaction Questionnaire (SSQ-8).

    Surgical Satisfaction Questionnaire (SSQ-8): is a validated questionnaire used to measure patient satisfaction following a surgery to correct prolapse and/or incontinence. Answers of the SSQ questions consisted of a 5-point scale ranging from "very satisfied" to "very unsatisfied" or from "yes" to "never". Patients' satisfaction is defined if answers correspond with "very satisfied" and "satisfied" or "yes" and "may be".

    Measured: 2 months ; 12 months ; Every year (at least 5 and up to 8 years)

  24. Percentage of patients satisfied after the index procedure as assessed by the Surgical Satisfaction Questionnaire (SSQ-8)

    Surgical Satisfaction Questionnaire (SSQ-8): is a validated questionnaire used to measure patient satisfaction following a surgery to correct prolapse and/or incontinence. Answers of the SSQ questions consisted of a 5-point scale ranging from "very satisfied" to "very unsatisfied" or from "yes" to "never". Patients' satisfaction is defined if answers correspond with "very satisfied" and "satisfied" or "yes" and "may be".

    Measured: 2 months ; 12 months ; Every year (at least 5 and up to 8 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Mar 2024
  2. Study start21 Nov 2023
  3. Primary completion6 Nov 2024
  4. Study completion6 Nov 2024

Why it stopped: From June 08, 2024, the study device was no longer marketed in France. Therefore, the sponsor decided to terminate the study prematurely.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
39 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06296316
Sponsor's protocol ID
IU022
Acronym
REPAIR
Status last verified
Jan 2026
First submitted
24 Nov 2023
Last updated
28 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: There is not a plan to make IPD available

Questions about this trial

What is this clinical trial studying?

An observational study of Genital Prolapse, run by Coloplast A/S at 6 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: From June 08, 2024, the study device was no longer marketed in France. Therefore, the sponsor decided to terminate the study prematurely.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The incidence rate of a surgical reintervention related to Restorelle mesh use over at least the 5 first years of post-index procedure follow-up (time frame: up to 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in